Guard Therapeutics appoints Michael Reusch as Chief Medical Officer
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Guard Therapeutics announces today that the company has appointed Dr. Michael Reusch as Chief Medical Officer. Dr. Reusch has over 30 years’ experience in global clinical development and regulatory processes from leading positions in the pharmaceutical industry, most recently in the role of Senior Medical Director at Astellas Pharma. He will take up his new position on 1 January 2022.
Dr. Michael Reusch is a physician and pharmacist who has previously worked at the global pharmaceutical companies Servier, Fujisawa and Astellas Pharma. He has also served as senior advisor to a number of other companies in the life science industry. Among other roles, he has led numerous drug development projects and interactions with regulatory authorities in the areas of chronic kidney disease and transplantation, most recently as a global medical lead for roxadustat, which is used to treat adult patients with symptomatic anaemia associated with chronic kidney disease, up to marketing authorisation in the EU and Japan.
“As our pharmaceutical development of ROSgard continues to advance, it is natural to expand the company’s internal pool of talent and resources, and we are very proud to have been able to attract such a senior professional as Michael Reusch. His long experience of global clinical drug development and interactions with regulatory authorities, not least in kidney disease and transplantation, will strengthen our ability to achieve continued success,” Guard Therapeutics’ CEO, Tobias Agervald, says.
Among other properties, the investigational drug ROSgard has the ability to counteract severe oxidative stress, which is a common denominator for many types of acute kidney injury. In the initial clinical development phase Guard Therapeutics has chosen to give priority to treatment in connection with open heart surgery using a heart-lung machine, where a major global phase 2 study is planned to start in the first quarter of 2022. There is also an option to expand the continued clinical programme to other segments, such as patients undergoing kidney transplantation.
For further information, please contact:
Tobias Agervald, CEO
Telephone: +46 8 670 65 51
E-mail: info@guardtherapeutics.com
Om Guard Therapeutics
Guard Therapeutics is a pharmaceutical company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s clinical investigational drug ROSgard is being developed as a protective treatment against acute kidney injury with an initial focus on patients undergoing heart surgery. Guard Therapeutics is listed on Nasdaq First North Growth Market Stockholm. The company’s Certified Adviser is Svensk Kapitalmarknadsgranskning AB, tel. +46 11 32 30 732, ca@skmg.se.